Arch Biopartners Adds Three Clinical Sites in Turkey For Phase II Trial for LSALT Peptide-- Arch Biopartners Inc., , which gained 2.7% yesterday, on Tuesday said that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and...